Neratinib

證據等級: L5

預測適應症: 4 個

Neratinib: From HER2-Positive Breast Cancer to Progesterone-Receptor Positive Breast Cancer

One-Sentence Summary

Neratinib is an irreversible pan-HER (HER1/HER2/HER4) tyrosine-kinase inhibitor established for HER2-positive breast cancer, most notably as extended adjuvant therapy after trastuzumab-based treatment. The TxGNN model predicts it may also be effective for progesterone-receptor positive breast cancer, with 5 clinical trials and 10 publications currently supporting this direction. Note: Finland market authorization and official original-indication text are not available in the current data — the original-indication statement above is drawn from published literature (ExteNET, NALA trials), not from a licensed package insert.

Quick Overview

Item	Content
Original Indication	Not available from Finland license records (drug not marketed); literature indicates HER2-positive breast cancer, extended adjuvant and metastatic settings
Predicted New Indication	Progesterone-receptor positive breast cancer
TxGNN Prediction Score	99.68%
Evidence Level	L2
Finland Market Status	未上市 (Not marketed)
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed, formally sourced mechanism-of-action data is not available in the current evidence pack. Based on the supporting literature, neratinib is an irreversible tyrosine-kinase inhibitor of HER1, HER2, and HER4, and its clinical activity in HER2-positive breast cancer (including the pivotal ExteNET phase 3 trial) is well established.

Progesterone-receptor (PR) positivity frequently co-occurs with HER2 positivity in the clinically important HR+/HER2+ breast cancer subgroup. In this subgroup, hormone-receptor signaling and HER2 signaling interact and can drive resistance to endocrine therapy alone, providing a mechanistic rationale for combining a pan-HER inhibitor like neratinib with endocrine agents (fulvestrant, aromatase inhibitors) or trastuzumab.

This is why the TxGNN prediction is plausible: it does not represent a leap to an unrelated disease, but an extension within the same tumor biology space where neratinib already has proven activity, targeting a hormone-receptor-defined subgroup of its established indication.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT04886531	Phase 2	Recruiting	30	Pre-operative neratinib plus endocrine therapy with trastuzumab in ER-positive, HER2-positive breast cancer; directly tests the neratinib + endocrine therapy combination relevant to PR+ disease
NCT06131424	N/A	Completed	1151	Multicenter retrospective study of HER2-low prevalence, clinicopathologic characteristics and treatment patterns in metastatic breast cancer; large real-world sample but non-interventional
NCT05599334	N/A	Completed	111	Retrospective observational study of neratinib as extended adjuvant therapy in early-stage HER2+ breast cancer under the European Early Access Program
NCT04901299	Phase 2	Withdrawn	0	Planned trial of fulvestrant plus neratinib in previously treated HR-positive, HER2-negative metastatic breast cancer; withdrawn, no data available
NCT04460430	Phase 2	Terminated	12	Neratinib targeting EGFR/ERBB2 in HR-positive/HER2-negative, HER2-enriched advanced/metastatic breast cancer; terminated early, small sample

Literature Evidence

PMID	Year	Type	Journal	Key Findings
26874901	2016	RCT	The Lancet. Oncology	ExteNET phase 3 trial: 12 months of neratinib after trastuzumab-based adjuvant therapy in early-stage HER2-positive breast cancer
27406346	2016	RCT	New England Journal of Medicine	I-SPY 2 adaptive phase 2 trial evaluating neratinib added to standard neoadjuvant chemotherapy in high-risk early breast cancer
35640077	2022	Review	J Clin Oncol	ASCO guideline update on systemic therapy for advanced HER2-positive breast cancer
29784737	2018	Review	JNCCN	NCCN Guidelines update for breast cancer, covering HER2-directed and endocrine-based regimens
32139271	2020	Review	Clinical Breast Cancer	BCTEG roundtable on clinical developments and practice guidance for HER2-positive breast cancer, including neratinib
33726508	2021	Review	Future Oncology	Current treatment trends in HR+/HER2+ breast cancer, discussing hormone plus anti-HER2 combinations without chemotherapy
24892840	2013	Review	Clin Adv Hematol Oncol	Integration of recent data into clinical practice for metastatic breast cancer across receptor subgroups
39153126	2024	Cohort	Breast Cancer Res Treat	Real-world patterns of adjuvant neratinib use and tolerance in HR+/HER2+ early-stage breast cancer, noting GI-related discontinuation
32782013	2020	Cohort	Breast Cancer Research	Targetable ERBB2 mutations as an adverse prognostic marker in ER-positive, ERBB2 non-amplified lobular breast carcinoma
35251981	2022	Cohort	Frontiers in Oncology	Case report and literature review on HER2-positive breast cancer with leptomeningeal disease

Finland Market Information

Neratinib currently has no marketing authorization on record in Finland (market status: 未上市, 0 authorizations). No dosage form or approved-indication data is available to populate a licensing table.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy (irreversible pan-HER tyrosine-kinase inhibitor)
Myelosuppression Risk	Low — no myelosuppression signal reported in the available literature; dominant toxicity is gastrointestinal (diarrhea), which drives treatment discontinuation in real-world cohorts
Emetogenicity Classification	Low to moderate
Monitoring Items	Liver function tests, diarrhea/GI tolerance, and standard CBC per oncology monitoring practice
Handling Protection	As an oral antineoplastic agent, standard institutional cytotoxic/hazardous drug handling precautions should apply pending official package insert confirmation

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The predicted PR+ breast cancer indication sits within neratinib's already-validated HER2-positive breast cancer biology, supported by an L2 evidence level (one completed Phase 2 observational trial plus a recruiting Phase 2 combination trial), but no trial to date is specifically stratified by PR status, so guardrails are warranted before advancing further.

To proceed, the following is needed:

TFDA/official package insert warnings and contraindications (currently blocking, DG001)
Formal DrugBank-sourced mechanism-of-action confirmation (DG002)
Finland market authorization and licensing status confirmation
A PR-status-stratified clinical trial or subgroup analysis to directly test the predicted indication
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.